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Poster Session II S271independently associated with platelet engraftment.While in pediat-
ric patients only infused CD34+ cells/kg was significantly associated
with platelet engraftment.
Graft-versus-host disease: At days 100, the cumulative incidence
was 55.0% for grade II-IV aGVHD, and 23.1% for grade III-IV
aGVHD. While cGVHD 44.67%, with 21.3% for limited and
23.3% for extensive. In patients under 14 years old, the cumulative
incidence of aGVHDof grade II-IVwas 57.2%, and 13.8% for grade
III-IV.While cGVHD 56.7% for total and 29.5% for extensive. No
associations of HLA disparity with incidence and severity of GVHD
were found.
KIR ligand mismatch and a higher dose of CD56bright NK cells
(41.9 106/kg) in the allografts are associated with high incidence of
aGVHD, while a higher CD56dim/CD56bri NK cell ratio (more
than 8.0) in allografts was correlated with a decreased risk of III-
IV aGVHD.
Relapse Tranplant-related mortality and survival: The 3-year
probability of relapse in the standard-risk group was 11.9%
and 24.3% for AML and ALL and that in high-risk group was
20.2% and 48.5% for AML and ALL, respectively. The advanced
disease status, Higher CD4/CD8 in G-BM and delayed lympho-
cyte recovery at day 30 post transplantation are correlated with
increased relapse rate. While, a higher CD56dim/CD56bri NK
cell ratio (more than 8.0) was correlated with a decreased rate
of relapse. Modified DLI can be used to treat relapse of patients
after the protocol.
The TRM on day 100 in the standard- and high-risk groups was
6.8% and 5.9% for AML and 6.9% and 25.9% for ALL, respectively.
The 3-year probability of LFS for AMLwas 70.7% and 55.9% and
for ALL was 59.7% and 24.8% in the standard-risk and high-risk
groups, respectively.304
IMMUNOSUPPRESSIVE CYTOKINE GENE POLYMORPHISMS AND OUT-
COMES AFTER RELATED AND UNRELATED HEMATOPOIETIC CELL
TRANSPLANTATION
Xiao, H., Lai, X., Wu, G., Luo, Y., Shi, J., Tan, Y., Han, X., Zhu, X.,
Zhu, J., Xie, W., He, J., Cai, Z., Lin, M., Ye, X., Huang, H. The First
Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,
Zhejiang, China
Background: Transforming growth factor-ß(TGFß) and IL10 are
pleiotropic regulatory cytokines in the immune system. Clinical
data and animal model suggest TGFß and IL10 can suppress
aGVHD. The present study was designed to test the influence of
gene polymorphisms of TGFß and IL10 on outcomes after related
and unrelated HSCT.
Methods:We analysed six single nucleotide polymorphisms (SNPs)
in three genes, TGFß1-509(C.T), +869 (T.C), TGFß1 receptor
II (TGFß1RII) +1167 (C.T) and IL10 -1082(A.G),
-819(T.C), -592(A.C), in a cohort of 138 pairs of recipients
and their unrelated donors and a second cohort of 102 pairs of recip-
ients and their HLA-identical sibling donors, who had undergone
HSCT from January 2001 to March 2009 at our center.
Results: (1) TGFß1 -509 T/T genotype in the donors side or T al-
lele-positive in the recipients side showed a significant protective ef-
fect on the occurrence of aGVHD and grade II-IV aGVHD in the
unrelated transplantation cohort (P\0.05). In the combined cohort,
the multivariate analysis confirmed that donors with TGFß1-509 T/
T genotype had a protective effect on the risk of aGVHD. (2) Both in
unrelated transplantation cohort and sibling transplantation cohort,
We found the IL10-819 C/C and -592 C/C genotype in either recip-
ients side or donors side were significantly associated with a higher
incidence of aGVHD (P\0.05). (3) In the combined cohort, the
promoter haplotypes of IL10 polymorphic features in positions
-1082, -819 and -592 had an influence on the occurrence of aGVHD
and death in remission. Recipients without A-T-A haplotype or were
transplanted from donors without A-T-A haplotype had a higher in-
cidence of aGVHD and death in remission than with A-T-A homo-
zygous or heterozygous. In multivariate analysis, recipients without
A-T-A haplotype was found to be associated with a higher risk of
aGVHD (RR5 0.764; P5 0.096) and grade II-IV aGVHD
(RR5 0.413; P5 0.009). (4) No significant association with
aGVHD was detected for the TGFß1 + 869, TGFß1RII +1167and IL10-1082 genotypes. No significant association was found be-
tween cytokine genes polymorphisms with cGVHD, relapse and
overall survival.
Conclusions:This is the first report of the relation of gene polymor-
phisms of IL10, TGFß1 and TGFß1RII to outcomes of allo-HSCT
within Chinese population. The results may provide useful informa-
tion to risk assessment, donor selection, and a guide for appropriate
immunosuppressive therapy.305
PTLD IN MINIATURE SWINE FOLLOWING NOVEL LOW INTENSITY CON-
DITIONING FOR HAPLOIDENTICAL HCT: THE MGH EXPERIENCE
Duran-Struuck, R.1, Teague, A.1, Crepeau, R.1, Matar, A.1,
Henakamp, I.1, Pathiraja, V.1, Veillette, G.1, Spitzer, T.R.2,
Sachs, D.H.1, Bronson, R.T.3, Huang, C.1 1Massachusetts General Hospi-
tal (Harvard Medical School), Boston, MA; 2Massachusetts General Hos-
pital (Harvard Medical School), Boston, MA; 3Harvard Medical School,
Boston, MA
Haploidentical HCT (haplo-HCT) is a potent and potentially cu-
rative therapy for a number of lymphohematopoietic neoplasms.
Haplo-HCT has been limited by toxic conditioning regimens and
the development of lethal graft-versus-host disease (GVHD). Similar
to what has been observed in the clinic, myeloablative HCT out-
comes in the pig have a high incidence of GVHD. Less toxic, non-
myeloablative haplo-HCTs developed in our laboratory resulted in
a greatly reduced incidence and intensity of GvHD. However,
post-transplantation lymphoproliferative disease (PTLD) was often
observed following these novel reduced intensity conditioning proto-
cols. Haplo-HCT conditioning with 700-1000 cGy thymic irradia-
tion (TI), CD3 immunotoxin and 30-60 days of cyclosporine had
a 6% incidence ofGVHD (2 of 32) but was complicated by a 33% in-
cidence of PTLD (11 of 32). Of these 11 pigs, 2 resolved their PTLD
after cyclosporine was discontinued but then developed GVHD.
When thymic irradiation was eliminated from the protocol, no
PTLD was observed and GVHD was only observed in 2 of 24
(8.3%) transplanted pigs. Unfortunately this very mild preparatory
regimen without TI failed to consistently achieve successful long
term engraftment. In an attempt to decrease the incidence of
PTLD, avoid GVHD and increase haplo-HCT engraftment out-
comes, 100 cGy of total body irradiation (TBI) was introduced to
the protocol.Of 46 haplo-HCTrecipients, only 4 (\10%) developed
PTLD and 2/46 animals developed GVHD, one of which recovered
spontaneously. We also attempted to identify serum markers for di-
agnosingPTLDin our pigs. As it is observed in humans,we identified
lactate dehydrogenase (LDH), to be elevated in pigs prior to onset of
PTLD. In support of these findings, three porcine PTLD tumor cell
lines harvested from animals and passaged in vitro demonstrate
higher LDH levels compared to naı¨ve PBMCs. We conclude that:
(1) our current haplo-HCT protocol utilizing 100 cGy TBI, porcine
CD3 immunotoxin and 45 days of cyclosporine is relatively safe and
significantly reduces the incidence of PTLD; (2) stable engraftment
and multilineage chimerism can be achieved with minimal GVHD;
and (3) LDH is a clinically relevant serum marker for the diagnosis
of PTLD in the pig. These findings reinforce the pigmodel as a valu-
able tool for HCT translational studies.306
CLOFARABINE6 FLUDARABINE WITH IV BUSULFAN AND ALLOGENEIC
STEM CELL TRANSPLANTATION FOR RELAPSED, REFRACTORY MYELOID
LEUKEMIA (ML) AND MDS
Andersson, B.S., de Lima, M., Valdez, B.C., Thall, P.F., Worth, L.L.,
Popat, U., Jones, R.B, Shpall, E.J., Madden, T., McAdams, P.L.,
Alousi, A.M., Rondon, G., Kebriaei, P., Champlin, R.E. University of
Texas M.D. Anderson Cancer Center, Houston, TX
Clofarabine (Clo) is a nucleoside analog (NA) with improved an-
tileukemic efficacy compared with Fludarabine (Flu), previously
used with IV Busulfan (Bu) in reduced toxicity conditioning therapy
for Allo-SCT. In vitro studies of [Clo + Flu + Bu] demonstrated a su-
perior synergistic cytotoxicity compared with either [Clo + Bu] or
[Flu + Bu].We have now investigated [Clo6 Flu] with IV Bu in pre-
transplant conditioning.
S272 Poster Session IIMethods and Patients: Patients were adaptively randomized, based
on day SCT +30 and chimerism status: Arm I Clo:Flu 10:30 mg/m2,
Arm II 20:20 mg/m2, Arm III 30:10 mg/m2, and Arm IV Clo at
40 mg/m2. The NA were/was infused over 60 min each once daily
for 4 d; then Bu was infused over 3 hrs to an average daily AUC of
6,000 mM-min. GVHD-prophylaxis was tacrolimus and mini-
MTX. Recipients of unrelated or one antig-mism related donor cells
received rabbit-ATG.
Results: 41 pts were enrolled, M:F 24:17, median age 45 yrs (range:
6-59). 32 pts had AML (ind. failure: 12, chemotherapy refr. relapse:
8, untreated relapse: 2, CR2 + CR2 p: 6, high-risk CR1: 1 [cytog. -7
and t(3;12)]). 17 of the 32 AML pts had intermediate, 15 had poor
prognosis cytogenetics. 9 pts had CML (BC: 2, second AP: 3, and
late CP: 4). Donors were 51% related; stem cell source was 61%
bone marrow or 39% peripheral blood.
All 41 pts engrafted. Peripheral blood (T-cell) chimerism at day
+30 revealed Arms I + II to have a median of 85% donor-derived
DNA, and Arms III + IV 100% donor-DNA; at day +100 all cohorts
had 100% donor-DNA.There were no secondary graft failures. Due
to the adaptive randomization, most pts were gradually allocated to
Arm III. 19 of the 23 pts with active AML and 7 of the 9 CML pts
enteredCR after SCT.We had 2 treatment-related deaths in the first
100 d (1 pneumonia and 1 GVHD). Grade 2-3 mucositis occurred in
about half the pts, but there were no serious toxicities. The median
follow-up is 16 months; one-year overall and event-free survival
are 52 and 40%, respectively.
Conclusions: 1) [Clo6 Flu] + IV Bu-based conditioning therapy is
safe and efficacious in high-risk pts withML/MDS. 2) The immuno-
suppressive capability of Clo allows its use in pretransplant condi-
tioning. 3) The in vitro studies which showed a superior
cytotoxicity of [Clo + Flu + Bu] than either [Clo + Bu] or [Flu + Bu]
were supported clinically by the better clinical outcomes in Arm
III. Additional pts and longer follow-up are needed to fully evaluate
the efficacy of [Clo + Flu + Bu] in pre-transplant conditioning.307
ASSESSMENT OF THE UTILITY OF SUBSET DONOR CHIMERISM FOR PRE-
DICTING EVENT-FREE SURVIVAL AFTER NON-MYELOABLATIVE ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION USING TLI AND ATG
Logan, A.C.1, Turnbull, B.B.2, Lavori, P.W.2, Miklos, D.B.1,
Negrin, R.S.1, Lowsky, R.1, Kohrt, H.E.1 1Stanford University School of
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Allogeneic hematopoietic cell transplantation (HCT) following
conditioning with total lymphoid irradiation (TLI) and antithymo-
cyte globulin (ATG) is an effective treatment modality for leukemia
and lymphoma.We recently reported 3-year event-free survival rates
for AML and NHL of 40% and 42%, respectively (Kohrt et al.,
Blood, 114:1099-1109). Disease relapse remains the primary cause
of treatment failure, thus the ability to predict when patients are at
risk for relapse would allow for timely immunologic interventions,
such as alterations of immunosuppressive therapy or donor lympho-
cyte infusions.We analyzed CD3/15/19/56 peripheral blood chime-
rism in 122 patients who underwent allo-HCT after TLI-ATG
conditioning between December 2001 and July 2009. Univariate
analysis comparing complete chimerism (.95% donor CD3) to
mixed chimerism (5-95% donor CD3) did not reliably predict events
(relapse or death). Several methods of evaluating the predictive value
of subset chimerism were then assessed, including Cox regression
analysis of chimerism trajectory, receiver operator characteristic
(ROC) analysis of chimerism trajectory, and ROC analysis of indi-
vidual chimerism measurements at days 90, 120, 150, and 180 after
HCT. Although subset chimerism generally performed poorly as
a predictor of outcome with all analytic strategies, ROC analysis of
chimerism trajectory and individual measurements demonstrated
limited utility for predicting event-free survival. We calculated the
area under the ROC curve (AUC), which represents the probability
that a randomly chosen patient with an observed event has lower chi-
merism than a randomly chosen patient without an observed event.
An AUC greater than 80% represents a high likelihood of event pre-
diction. For patients with lymphoid malignancies, all subsets ex-
hibited poor predictive value using all methods, and with ROC
analysis the AUC was uniformly less than 70% for all subset-time-point combinations. In patients with myeloid malignancies, only
CD15 chimerism was predictive of event-free survival, with AUC
values of 84% at day 90, 79% at day 120, 82% at day 150 and 88%
at day 180. We conclude that subset donor chimerism has little util-
ity for predicting event-free survival in lymphoid malignancies, and
that only CD15 chimerism predicts outcome in myeloid malignan-
cies. Additional patient characteristics will need to be incorporated
into the decision to apply immunological therapies to alter outcome
after non-myeloablative HCT.308
LOW CD4 T-LYMPHOCYTE REACTIVITY BY THE CYLEX IMMUKNOW AS-
SAY PREDICTS VIRAL INFECTIONS FOLLOWING ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Farag, S.S.1, Wood, L.1, Schwartz, J.1, Nelson, R.P.1, Srivastava, S.1,
Secrest, A.1, Cox, E.1, Robertson,M.1, Abonour, R.1, Lobashevsky, A.2 1 In-
diana University School of Medicine and Simon Cancer Center, Indianap-
olis, IN; 2 Indiana University School of Medicine, Indianapolis, IN
Viral infections are a significant cause ofmorbidity after allogeneic
stem cell transplantation. Modifying intensity of immunosuppres-
sion according to immune function may reduce infections. Cur-
rently, no routine functional assays to monitor immune function of
the new graft exist. The Cylex ImmuKnow assay is a FDA approved
test that quantifies cellular immune function by measuring intracel-
lular ATP activity released by PHA-stimulated CD4 T cells in
blood, and has correlated with solid organ graft outcomes.
We correlated ATP activity with viral infections in the first 100
days post-transplant. 341 blood samples were collected q1-3 weeks
from 32 patients of median age 42 (21-59) years undergoing related
(14) or unrelated (18) donor transplants. All received myeloablative
doses of chemotherapy6TBI, with ATG in 14 patients. GvHDpro-
phylaxis included FK506 with sirolimus (28) or methotrexate (4).
CMV and EBV load was monitored in plasma by PCR q1-2 weeks
and preemptive therapy started on reactivation with other viral test-
ing as clinically indicated. 14 patients developed infections while on
GvHD prophylaxis, including CMV (10), EBV (3), BK hemorrhagic
cystitis (8), adenovirus gastritis (1), and HSV pneumonitis (1).
Baseline median ATP activity for all patients was 280 (5-809) ng/
ml, compared to 491 (238-842) ng/ml for healthy volunteers
(P\0.0001). ATP activity only modestly correlated with lympho-
cyte (R25 0.21) and WBC (R25 0.45) counts. Median ATP activi-
ties were lower for patients who developed infections between days
+31 and +60 (31 vs 106 ng/ml, P5 0.0007), and days +61 and +100
(34 vs 139 ng/ml, P5 0.0006). On logistic regression, low ATP ac-
tivity was predictive of infections (P\0.0001), but lymphocyte and
WBC counts were not. Using 90 ng/ml as cutoff, 11 of 20 patients
with ATP activity\100 ng/ml developed infections compared to 1
of 12 with activity $100 ng/ml between days +31 and +60
(P5 0.01). Between days +60 and +100, 9 of 12 patients with levels
\90 ng/ml developed infections, compared to 1 of 14 patients with
levels $90 ng/ml (P5 0.001). Median ATP activity was 251 (97-
494) ng/ml at the onset of grade 2-4 acute GvHD that occurred in
4 patients. Our results indicate that low ATP activity in CD4 T cells
is strongly predictive of viral infections in the first 100 days after
transplant, and suggest that modifying the intensity of immunosup-
pression to maintain ATP activity around 90 ng/ml should be inves-
tigated as a strategy to reduce infections.309
AZITHROMYCIN FOR BRONCHIOLITIS OBLITERANS FOLLOWING ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Maciuleviciute, E.1, Burzynski, J.A.1, Wolf, R.C.1, Ansell, S.M.2,
Buadi, F.K.2, Dingli, D.2, Dispenzieri, A.2, Gastineau, D.A.2,
Gertz, M.A.2, Inwards, D.J.2, Johnston, P.B.2, Kumar, S.2,
Lacy, M.Q.2, Litzow, M.R.2, Micallef, I.N.M.2, Porrata, L.E.2,
Hogan,W.J.2 1Mayo Clinic, Rochester,MN; 2Mayo Clinic, Rochester,MN
Background: Bronchiolitis obliterans (BO) following HSCT is as-
sociated with significant morbidity and mortality with few effective
